De Cosmo, S., Motterlini, N., Prudente, S., Pellegrini, F., Trevisan, R., Bossi, A., . . . Ruggenenti, P. (2009). Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. American Diabetes Association.

De Cosmo, Salvatore, Nicola Motterlini, Sabrina Prudente, Fabio Pellegrini, Roberto Trevisan, Antonio Bossi, Giuseppe Remuzzi, Vincenzo Trischitta, i Piero Ruggenenti. Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy On New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. American Diabetes Association, 2009.

De Cosmo, Salvatore, et al. Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy On New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. American Diabetes Association, 2009.